logo

Auris Medical Holding Ag (EARS)



Trade EARS now with
  Date
  Headline
8/30/2018 8:16:37 AM Auris Medical Gets FDA Guidance At Type C Meeting For AM-111 In Treatment Of Sudden Sensorineural Hearing Loss
8/15/2018 6:48:48 AM Auris Medical Q2 Net Loss CHF 3.1 Mln Or CHF 0.50/Shr Vs Loss CHF 5.4 Mln Or CHF 1.22/Shr Last Year
5/30/2018 7:46:47 AM Auris To Host Key Opinion Leader Call Focused On AM-201 Program For Treating Major Side Effects Of Antipsychotics
5/15/2018 6:47:58 AM Auris Medical Q1 Net Loss CHF 1.7 Mln Or CHF 0.30/Shr Vs Loss CHF 8.4 Mln Or CHF 2.15/Shr Last Year
5/4/2018 6:48:47 AM Auris Medical Announces Publication Related To AM-111 In Peer-Reviewed Scientific Journal
4/9/2018 6:49:38 AM Auris Medical Announces Voluntary Early Repayment Of Part Of Its Loan Facility With Hercules Capital
3/29/2018 7:03:40 AM Auris Regains Compliance With Nasdaq's Minimum Bid Price Requirement
3/13/2018 4:29:11 PM Auris Medical Holding Trading Expected To Resume At 4:45PM ET
3/13/2018 4:16:54 PM Auris Medical Holding Trading Halted; Pending News
1/4/2018 8:30:30 AM Auris Medical Says HEALOS Trial Not Met Primary Efficacy Endpoint In Overall Study Population
11/28/2017 6:42:30 AM Auris Medical Q3 Net Loss CHF 6.0 Mln Or CHF 0.14/Shr Vs CHF 7.9 Mln Or CHF 0.23/Shr Last Year
11/28/2017 6:41:20 AM Auris Medical Reports Top-Line Results From Phase 3 Trial Of AM-111 In Sudden Deafness